Immune Recovery in Adult Patients after Myeloablative Dual Umbilical Cord Blood, Matched Sibling, and Matched Unrelated Donor Hematopoietic Cell Transplantation  by Kanda, Junya et al.
From the
Duke
2Depa
Durh
Huma
Durh
Unive
ment
Medic
Hema
Saitam
Financial d
Correspon
Divisi
Unive
Durh
Received F
 2012 Am
1083-8791
http://dx.d
1664Immune Recovery in Adult Patients after
Myeloablative Dual Umbilical Cord Blood, Matched
Sibling, and Matched Unrelated Donor Hematopoietic
Cell Transplantation
Junya Kanda,1,6 Lun-Wei Chiou,1 Paul Szabolcs,2 Gregory D. Sempowski,3
David A. Rizzieri,1 Gwynn D. Long,1 Keith M. Sullivan,1 Cristina Gasparetto,1 John P. Chute,1
Ashley Morris,1 Jacalyn McPherson,1 Jeffrey Hale,3 John Andrew Livingston,1
Gloria Broadwater,4 Donna Niedzwiecki,5 Nelson J. Chao,1 Mitchell E. Horwitz1Immunologic reconstitution after allogeneic hematopoietic cell transplantation is a critical component of suc-
cessful outcome. Umbilical cord blood (UCB) transplantation in adult recipients is associated with slow and
often inadequate immune recovery.We characterized the kinetics and extent of immune recovery in 95 adult
recipients after a dual UCB (n 5 29) and matched sibling donor (n 5 33) or matched unrelated donor
(n 5 33) transplantation. All patients were treated with myeloablative conditioning. There were no differ-
ences in the immune recovery profile of matched sibling donor and matched unrelated donor recipients. Sig-
nificantly lower levels of CD31, CD41, and CD81 T cells were observed in UCB recipients until 6 months
after transplantation. Lower levels of regulatory T cells persisted until 1 year after transplantation. Thymo-
poiesis as measured by TCR rearrangement excision circle was comparable among all recipients by 6 months
after transplantation. In a subset of patients 1 year after transplantation with similar levels of circulating T
cells and TCR rearrangement excision circle, there was no difference in TCR diversity. Compared to
HLA-identical matched sibling donor and matched unrelated donor adult hematopoietic cell transplantation
recipients, quantitative lymphoid recovery in UCB transplantation recipients is slower in the first 3 months,
but these differences disappeared by 6 to 12 months after transplantation.
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Allogeneic hematopoietic cell transplantation
(HCT) is an established cellular therapy for patients
with hematologic malignancies, bone marrow (BM)
failure syndrome, and immune disorders [1]. After
myeloablative allogeneic HCT, host immunity is ab-
lated by the conditioning regimen. Immunologic re-
constitution arises from maturation of donor stem
cell-derived lymphoid progenitors and peripheral ex-
pansion of mature immune cells included in the donor
graft [2,3]. During the initial neutropenic phase of the
HCT, recipients have a high risk of bacterial infection.
However, a profoundly immunocompromised state
continues after neutrophil engraftment due to
deficiencies or impairment of cellular immune
reconstitution. Initial cellular immune reconstitution
after HCT largely depends on thymic-independent
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cells. This is followed by thymic-dependent matura-
tion of stem cell-derived lymphoid progenitor cells
[2,3]. Because the repertoire of peripherally expanded
memory T cells is limited, thymic-dependent matura-
tion is important for diversification of the T cell reper-
toire and strengthening host defense against pathogens
and even recurrence of malignancy.
Unrelated umbilical cord blood (UCB) has
emerged as a viable alternative source of hematopoietic
stem cells for adult and pediatric allogeneicHCT [4-6].
In contrast to peripheral blood or BM grafts, UCB
grafts contain few, if any antigen-specific memory T
cells and a higher proportion of na€ıve T cells. This
limits the potential for thymic-independent immune
recovery [7-10] and is felt to be one of the main
reasons why adult UCB HCT recipients are more
prone to viral infections compared with patients
receiving peripheral blood or BM stem cell grafts.
The challenge of posttransplantation immune
reconstitution is further complicated in adult patients
as a consequence of thymic atrophy, thereby limiting
the thymic-dependent pathways of lymphopoiesis
[11,12]. Available data suggest exceedingly slower and
less robust immune recovery after adult UCB
transplantations thanpediatricUCBtransplantations [9].
Although immune reconstitution after UCB trans-
plantation has been evaluated by several groups
[7-9,13], there are limited data on how it compares
after HCT from other graft sources [14]. We present
here results of a comprehensive comparison of im-
mune recovery in adult patients after T cell-replete
myeloablative conditioning and allogeneic dual
UCB, matched sibling donor (MSD), or matched un-
related donor (MUD) HCT.METHODS
Patients
Reconstitution of immune cell populations was
prospectively characterized in a consecutive cohort of
146 adult patients ($18 years old) with hematological
malignancies undergoing T cell replete myeloablative
HCT, using MSD or MUD peripheral blood stem
cells (PBSCs), or dual UCB donor grafts, between
April 2006 and December 2010. PBSC recipients
were conditioned with either a total body irradiation
(TBI)-based regimen (TBI $ 12 Gy) or i.v. busulfan
(12.8 mg/kg) (Bu)-based regimen, andUCB transplan-
tation recipients were conditioned with a TBI ($13.2
Gy) and fludarabine (160mg/m2) (Flu)-based regimen.
No patient received in vivo (such as antithymocyte
globulin [ATG]) or ex vivo T cell depletion. The algo-
rithm for donor selection was MSD first, followed by
an MUD, followed by UCB. PBSC grafts were
allele-level matched at HLA-A, HLA-B, HLA-C,and HLA-DRB1, whereas dual UCB grafts were at
least 4 of 6 HLA-matched with the recipient, and 3
of 6 HLA-matched between grafts (low-resolution
for A and B, and high-resolution for DRB1). A total
of 34 patients with primary or secondary graft failure
(UCB recipients, n 5 7; MSD/MUD recipients,
n 5 1) or those who died or relapsed within 3 months
after HCT (UCB recipients, n 5 11; MSD recipients,
n 5 10; MUD recipients, n 5 5) were excluded from
the analysis of immune reconstitution to focus on
comparing immune recovery 3 to 12 months after
transplantation. An additional 17 patients (UCB recip-
ients, n 5 3; MSD/MUD recipients, n 5 14) were not
evaluable due to lack of immune recovery data collec-
tion. As a result, 95 patients were included in the analy-
sis of immune reconstitution. In addition to these 95
patients, all consecutive patients (n 5 146) were in-
cluded in the progression-free survival (PFS) outcomes
analysis. Standard-risk diseases were defined as acute
myelogenous leukemia (AML) in first or second com-
plete remission, acute lymphoblastic leukemia (ALL)
in first or second complete remission, myelodysplastic
syndromes; refractory anemia or refractory anemia
with excess of blasts-1, Hodgkin or non-Hodgkin lym-
phoma in any chemotherapy sensitive remission,
chronic myelogenous leukemia in first or second
chronic phase, and myelofibrosis. High-risk diseases
were those other than standard-risk disease.All research
sampleswere collected after obtainingwritten informed
consent for participation in accordance with theDecla-
ration of Helsinki on a protocol approved by the Duke
UniversityMedical Center Institutional Review Board.Measurement of Immune Recovery
Quantification of the following subsets was per-
formed by flow cytometry on fresh peripheral blood at
approximately 1 month before transplantation and
then 1.5, 3, 6, and 12 months after transplantation
[15,16]: natural killer (NK) (CD32, CD161/CD561)
and natural killer T cells (NKT) (CD31, CD161/
CD561) cells, B cells (CD191, CD32, CD162,
CD562), CD31, CD41, CD81, regulatory (CD41,
CD251, CD62L1), cytotoxic/late memory (CD81,
CD571, CD282), and activated (CD81, HLA-
DR1) T cells, na€ıve CD41 T cells with L-selectin ex-
pression, which is suggestive of recent thymic emigrants
(RTEs) (CD41, CD45RA1/CD45RO2, CD62L1),
plasmacytoid dendritic cells (DCs) (CD1231,
CD11c2), and myeloid DCs (CD1232, CD11c1).
Quantification of recent thymic immigrants as de-
termined by the presence of TCR rearrangement exci-
sion circles (TREC) was retrospectively performed by
real-time quantitative-PCR of DNA collected from an
isolated fraction of CD31 T cells, as previously de-
scribed [17]. Samples were analyzed in duplicate and
expressed as TREC per 10,000 CD31 T cells.
1666 Biol Blood Marrow Transplant 18:1664-1676, 2012J. Kanda et al.Spectratyping was performed to analyze diversity in
the TCR repertoires produced by the rearrangements
of the variable region genes [18,19]. Selected cDNA
samples underwent survey-level sequencing for
TCR-b repertoire analysis (Adaptive TCR Corpora-
tion with ImmunoSeq) [20,21]. A standard algorithm
was used to identify which V, D, and J segments
comprised each TCR-b CDR3. Sequence reads
from each donor T cell sample were determined to
be productive or nonproductive based on CDR3
sequences. CDR3 sequences that could result in
a functional TCR were considered to be productive
rearrangements. Entropy (ie, Shannon Entropy), a
measure of the uniformity of the frequency
distribution of a TCR-b repertoire, was performed
for productive clones as follows: Entropy 5 sum over
all clones of 21 * [(frequency of clone) * (log2
frequency of clone)]. Entropy is reported in bits, and
it ranges from 0 in a sample with only one clone to
log2 (No. of unique clones) for a sample with a
uniform distribution of clone frequencies. Monoclonal
or oligoclonal samples have low entropy, and
polyclonal highly diverse samples have an entropy
just under log2 (No. uniques).Statistical Analysis
Themean ages for the 3 transplantation types were
compared using the analysis-of-variance test. The me-
dian follow-up periods of survivors were compared us-
ing the Kruskal-Wallis test. The Pearson chi-square
test of proportions was used to compare associations
between clinical factors and transplantation type.
TheWilcoxon rank-sum test was used to compare im-
mune recovery parameters at approximately 1 month
before transplantation and 1.5, 3, 6, and 12 months af-
ter transplantation, adjusting P values for multiple
comparison with the Adaptive Holms step-down Bon-
ferroni method [22]. The same method was also used
to compare the number of TRECs at 1 month before
transplantation and 3, 6, and 12months posttransplan-
tation. Acute graft-versus-host-disease (aGVHD) or
chronic graft-versus-host disease (cGVHD) was char-
acterized using standard criteria [23,24].
Cytomegalovirus (CMV) reactivation was defined as
positive if more than 200 copies of CMV were
amplified in peripheral blood by real-time quantitative
PCR. The actual probabilities along with 95% confi-
dence intervals (CIs) of aGVHD and cGVHD, CMV
reactivation and disease, and treatment-related mor-
tality (TRM) were estimated on the basis of cumulative
incidence curves to accommodate the following com-
peting events [25]: death without GVHD for aGVHD
and cGVHD, death without CMV reactivation/dis-
ease for CMV reactivation/disease, and relapse for
TRM; the groups were compared using the Gray test
[26]. Cumulative corticosteroid usage beginning onthe day of transplantation until the 3-month, 6-month,
or 1-year time point after transplantation was deter-
mined by the area under the curve (AUC) [27]. The
central tendency of corticosteroid AUC was compared
using the Wilcoxon rank-sum test. TCR diversity, ex-
pressed as an Entropy score, was compared using the t
test. PFSwas defined as the period from 3months after
transplantation until disease progression or death,
whichever occurred first and censored at time of last
follow-up. The probability of PFS was estimated ac-
cording to the Kaplan-Meier method, and groups
were compared using the log-rank test. Cox propor-
tional hazards multivariate regression modeling was
used to predict PFS. The following variables were an-
alyzed in a bivariate model adjusted for donor type
(MSD/MUD or UCB) as well as in a univariate model
in the MSD/MUD group: recipient age (#41 (median
age) or .41), recipient sex, disease (myeloid or lym-
phoid disease), type of conditioning regimen (TBI-
based or Bu-based regimen), GVHD prophylaxis (cy-
closporine-based or tacrolimus-based, or other),
aGVHD (no and grade I or grade II-IV aGVHD),
and each lymphocyte subset at 3 months after trans-
plantation dichotomized at the median value. Due to
few events, a parallel analysis was not performed in
the UCB group. All tests were 2-sided, and a P value
of less than .05 was considered to indicate statistical
significance. All statistical analyses were performed us-
ing SAS (SAS Institute, Cary, NC) and Stata (Stata
Corp., College Station, TX).RESULTS
Patient Characteristics
Patient characteristics are shown in Table 1. The
UCB recipients (mean age, 36; range, 19-55 years)
were younger than MSD recipients (mean age, 45;
range, 24-65 years) and MUD recipients (mean age,
41; range, 20-56 years; P\ .01). All UCB recipients re-
ceived a myeloablative dose of TBI and Flu as a part of
a conditioning regimen, whereas half of MSD/MUD
recipients received a non-TBI, Bu-based conditioning
regimen. Two-thirds of all patients received transplan-
tations for AML or myelodysplastic syndromes. Most
of the UCB and MUD recipients received
tacrolimus-based GVHD prophylaxis, whereas 40%
of the MSD recipients received cyclosporine-based
GVHD prophylaxis.
The median combined total nucleated cell dose for
the UCB recipients was 4.6 (range, 3.3-8.6;
n 5 29)  107/kg. Each unit of the UCB graft con-
tained a minimum of 1.5  107/kg. The median total
nucleated cell dose for the MSD and MUD grafts
was 13.0 (range, 3.6-31.7; n 5 31)  108/kg and 8.1
(range, 3.2-15.1; n 5 32)  108/kg, respectively, and
the median CD341cell dose for the MSD and MUD
Table 1. Patient Characteristics
Characteristics UCB (n 5 29)
Matched Sibling Peripheral
Blood (n 5 33)
Matched Unrelated Peripheral
Blood (n 5 33) P Value
Age, years, mean (range) 36 (19-55) 45 (24-65) 41 (20-56) <.01
Recipient sex .44
Female 12 (41%) 16 (48%) 19 (58%)
Male 17 (59%) 17 (52%) 14 (42%)
Disease *
Myeloid disease
AML 18 (62%) 16 (48%) 21 (64%)
CML 2 (7%) 3 (9%) 1 (3%)
MDS 2 (7%) 6 (18%) 3 (9%)
MF 0 (0%) 2 (6%) 0 (0%)
Lymphoid disease
ALL 5 (17%) 5 (15%) 5 (15%)
ML 2 (7%) 1 (3%) 3 (9%)
Disease risk .58
Standard 25 (86%) 25 (76%) 26 (79%)
High 4 (14%) 8 (24%) 7 (21%)
AML/ALL <.01
CR1 5 (22%) 10 (48%) 14 (54%)
CR2 16 (70%) 5 (24%) 10 (38%)
CR3+ 2 (9%) 6 (29%) 2 (8%)
History of previous chemotherapy (ML) .60
#3 courses 2 0 2
>4 courses 0 1 1
Conditioning regimen <.01
TBI-based 29 (100%) 14 (42%) 19 (58%)
TBI + cyclophosphamide 0 10 16
TBI + etoposide 0 3 3
TBI + Flu 20 1 0
TBI + Fu + cyclophosphamide 6 0 0
TBI + Fu + thiotepa 3 0 0
Bu-based 0 (0%) 19 (58%) 14 (42%)
Bu + cyclophosphamide 0 9 12
Bu + Flu 0 10 2
GVHD prophylaxis <.01
Cyclosporine-based 5 (17%) 13 (39%) 0 (0%)
Cyclosporine + methotrexate 0 12 0
Cyclosporine + MMF 5 0 0
Cyclosporine + sirolimus 0 1 0
Tacrolimus-based 24 (83%) 20 (61%) 33 (100%)
Tacrolimus + methotrexate 0 17 31
Tacrolimus + MMF 24 0 0
Tacrolimus + sirolimus 0 3 2
CMV serostatus .52
Negative for both recipient and donor 5 (17%) 7 (21%) 3 (9%)
Positive for either recipient or donor 20 (69%) 19 (58%) 21 (64%)
Indeterminate/unknown 4 (14%) 7 (21%) 9 (27%)
Median follow-up period of survivors,
months (range)
25.3 (3.7-57.5) 21.1 (4.2-46.3) 24.5 (3.7-47.9) .91
UCB indicates unrelated cord blood; AML, acute myelogenous leukemia; CML, chronic myelogenous leukemia; MDS, myelodysplastic syndrome; MF,
myelofibrosis; ALL, acute lymphoblastic leukemia; ML, malignant lymphoma; TBI, total body irradiation; Flu, fludarabine; Bu, busulfan; GVHD, graft-
versus-host disease; MMF, mycophenolate mofetil; cyclosporine-based, cyclosporine with or without other agents; tacrolimus-based, tacrolimus with
or without other agents; CMV, cytomegalovirus.
*No statistical test is provided due to small sample size.
Biol Blood Marrow Transplant 18:1664-1676, 2012 1667Immune Recovery after Dual UCB and MSD/MUD HCTgrafts was 5.2 (range, 1.9-11; n5 32) 106/kg and 7.5
(range, 2.4-9.7; n 5 32)  106/kg, respectively.Immune Recovery
Because there were no significant differences in the
kinetics of immune recovery and PFS between MSD
and MUD recipients (Supplemental Figure 1), data
on immune recovery of MSD and MUD recipients
were combined and then compared with those of
UCB recipients (Figure 1). The absolute lymphocyte
count was lower in the UCB recipients at 1.5 monthsafter transplantation but reached the same level as
MSD/MUD recipients by 3 months after transplanta-
tion. The number of CD31, CD41, and CD81 cells
was significantly lower in the UCB recipients at 1.5
and 3 months after transplantation. This trend contin-
ued at the 6-month time point, but the difference was
no longer statistically significant. At 12 months after
transplantation, there was no detectable difference in
CD31, CD41, and CD81 T cell counts in the
UCB recipients and the MSD/MUD recipients. Re-
covery of B cells was highly variable in the UCB recip-
ients. Overall, B cell recovery was faster in the UCB
Figure 1. Sequential changes of immune cell populations after transplantation. Black line showsmatched sibling donor/matched unrelated donor (MSD/
MUD) recipients, and dotted line shows umbilical cord blood (UCB) recipients. The median values are shown as dots, and the ends of the whiskers
indicate the 25% and 75% percentile values. Available median and 5%/95% percentiles of healthy adults are shown in dotted and solid horizontal lines
[44]. RTE, recent thymic emigrant; T-reg, regulatory T cell; CTL, cytotoxic T lymphocyte; DC, dendritic cells.
1668 Biol Blood Marrow Transplant 18:1664-1676, 2012J. Kanda et al.recipients than the MSD/MUD recipients at 6 months
after transplantation, but this difference was lost by 12
months. The NK cell counts were significantly higherin the UCB recipients at 3, 6, and 12 months after
transplantation. Recent thymic emigrant (na€ıve
CD41T cells with CD62L expression) and regulatory
Figure 2. Sequential changes in TCR rearrangement excision DNA cir-
cles (TRECs) before and after transplantation.
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significantly lower in the UCB recipient at 1.5, 3,
and 6 months after transplantation. Cytotoxic T
cell (CD81CD571CD282) and activated T cell
(CD81HLADR1) counts were lower in the UCB re-
cipients at 1.5 and 3 months after transplantation.
There was no significant difference in the plasmacy-
toid dendritic cell counts, whereas the myeloid den-
dritic cell counts were higher in the UCB recipients
at 1.5 months after transplantation. The number of
NKT cells was significantly lower in UCB recipients
throughout the period of observation.TREC and TCR-b Repertoire
To further evaluate thymic-dependent T cell re-
covery, we measured TREC levels for 11 UCB and
21 MSD/MUD recipients. TREC levels were lower
in the UCB recipients at 3 months after transplanta-
tion but comparable by the 6-month time point.
TREC levels were uniformly low regardless of donor
type, even at 12 months after transplantation
(Figure 2). The median TREC level per 105 CD31
T cells for the UCB and MSD/MUD recipients was
80 (range, 0-40; n 5 9) and 415 (range, 0-4460;
n 5 20; P 5 .04) pretransplantation, 62 (range,Table 2. TCR Repertoire
Donor Type TREC (100,000 CD3+ cells) Productive Total
MSD 1 2140 711514
MSD 2 1046 485
MSD 3 1970 6653
MUD 1 4080 633850
MUD 2 1262 493739
MUD 3 1982 547860
UCB 1 2400 42526
UCB 2 784 519744
UCB 3 436 92930
UCB 4 598 174762
MSD indicates matched sibling donor; MUD, matched unrelated donor; UCB,
*Entropy is a measure of the uniformity of the frequency distribution of a TCR
polyclonal highly diverse samples have an entropy just under log2 (No. unique0-482; n 5 10) and 209 (range, 0-4,680; n 5 20;
P 5 .09) at 3 months posttransplantation, 414 (range,
0-14,740; n 5 11) and 232 (range, 0-4,200; n 5 21;
P 5 .86) at 6 months posttransplantation, and 517
(range, 14-2,400; n 5 10) and 244 (range, 0-6,900;
n5 19; P5 .87) at 12 months posttransplantation, re-
spectively. TCR diversity was assessed via survey-level
TCR-b sequencing on a subset of 10 patients (MSD,
n 5 3; MUD, n 5 3; UCB, n 5 4) who demonstrated
comparable levels of TREC-positive cell recovery at
12 months (Table 2). Representative profiles of TCR
Vb gene usage in peripheral blood T cells from recip-
ients of MSD, MUD, UCB, and a healthy control are
shown in Figure 3. TCR diversity (Entropy value;
healthy control, 11.95) in the UCB recipients
was comparable to that of the MSD/MUD recipients
(average [SD] of entropy value; UCB, 9.33 6 3.85;
MSD/MUD, 7.71 6 2.26; P 5 .47).GVHD and Corticosteroid Exposure
To thoroughly assess the potential confounding
effect of GVHD on posttransplantation immune re-
covery, we compared the cumulative incidence of
grade II to IV and grade III to IV aGVHD and
cGVHD (Figure 4). The incidence of grade II to IV
aGVHD was significantly higher among the UCB re-
cipients compared with the MSD/MUD recipients
(0.66 [95% CI, 0.45-0.80] vs 0.38 [95% CI,
0.26-0.50, respectively]; Gray test, P 5 .006). The in-
cidence of grade III to IV aGHVD was also higher in
the UCB vs MSD/MUD recipients (0.28 [95% CI,
0.13-0.45] vs 0.09 [95% CI, 0.04-0.18, respectively];
Gray test, P 5 .018). Conversely, there was no signif-
icant difference in the incidence of cGVHD at 1 year
between the UCB and MSD/MUD recipients (0.48
[95% CI, 0.29-0.65] vs 0.37 [95% CI, 0.25-0.49, re-
spectively]; Gray test, P 5 .128). Because the persis-
tence and treatment responsiveness of GVHD may
differ depending on graft source, we assessed cumula-
tive corticosteroid exposure (mg/kg) from 0 to 3, 6, orProductive Uniques
Entropy*
P ValueValue Ave. (±SD)
10500 11.84 9.33 (±3.85) ref.
15 3.02
158 6.02
7532 11.27
11957 11.90
13300 11.93
467 7.49 7.71 (±2.26) .47
9128 10.61
1981 5.10
1445 7.62
umbilical cord blood; Ave., average; ref., reference.
-b repertoire. Monoclonal or oligoclonal samples have low entropy, and
s). The value of Entropy in a healthy control was 11.95.
Figure 3. Representative profiles of TCRVb gene usage in peripheral blood T cells from recipients of matched sibling donor (MSD) (A), matched un-
related donor (MUD) (B), umbilical cord blood (UCB) transplantation (C), and healthy control (D).
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with the observed differences in clinical GVHD, the
cumulative corticosteroid exposure at 3 months and
6 months after transplantation was significantly higher
in the UCB recipients than in the MSD/MUD recipi-
ents. However, at 12 months after transplantation,
there was no difference in cumulative corticosteroid
exposure between the 2 groups. We also evaluated
the cumulative corticosteroid exposure only for those
who received corticosteroid treatment for GVHD.
The cumulative corticosteroid exposure at 3, 6, or
12 months was not statistically different between the
3 groups, suggesting treatment response to GVHD
was similar regardless of the donor type (Table 3).
We then evaluated the impact of grade II to IV and
III to IV aGVHD on immune recovery at 3, 6, and 12
months after transplantation. We found that grade III
to IV aGVHD (but not grade II to IV) significantly de-
layed the recovery of several immune cell populations
at 3 months after transplantation (data not shown).
Grade II to IV or III to IV aGVHD did not have any
impact on immune recovery at 6 and 12 months after
transplantation. Therefore, we performed an addi-
tional analysis in which we compared the immune re-
covery of the UCB group with that of the MSD/
MUD group in patients with grade 0 to I vs grade II
to IV aGVHD or patients with grade 0 to II vs grade
III to IV aGVHD (Table 4). Regardless of the pres-
ence of grade II to IV aGVHD, immune cell recovery
other than B or NK cells was slower in the UCB group
as compared with the MSD/MUD group. Among pa-
tients with grade III to IV aGVHD, median values of
immune cell populations were lower in theUCB group
than in theMSD/MUDgroup, although it was not sig-
nificant partly due to the small sample size and partly
due to the impact of grade III to IV aGVHD on im-
mune cell recovery.We additionally attempted to identify differences
in the number of specific lymphocyte populations in
those who did and did not develop cGVHD. We did
not find any significant difference in these 2 groups
for each immune cell population (data not shown).
CMV Reactivation and Disease
The cumulative incidence of CMV reactivation
among patients at risk of CMV reactivation (serosta-
tus; positive for either recipient or donor) was 0.84
(95% CI, 0.55-0.95) and 0.53 (95% CI, 0.36-0.67) in
the UCB and MSD/MUD recipients, respectively
(Gray test, P 5 .046; Figure 5), which corresponded
with delayed recovery of T cells in the UCB recipients.
The cumulative incidence of CMV diseases was 0.21
(0.07-0.41) and 0.03 (0.002-0.11) in the UCB and
MSD/MUD recipients, respectively (Gray test,
P5 .019). All cases of CMV disease involved the intes-
tinal tract, and none of the patients died from CMV
disease. To exclude the effect of aGVHD on CMV re-
activation and disease, we further evaluated the cumu-
lative incidence of CMV in the UCB and MSD/MUD
recipients according to the presence of grade II to IV
aGVHD. The incidence of CMV reactivation and dis-
ease was consistently higher in the UCB group com-
pared to the MSD/MUD group (CMV reactivation;
grade 0-I aGVHD, 57% vs 36%, P 5 .574; grade II
to IV aGVHD, 100% vs 72%, P5 .169; CMV disease,
grade 0 to I aGVHD, 14% vs 0%, P5 .076; grade II to
IV aGVHD, 25% vs 6%, P5 .137), although these dif-
ferences were not statistically significant due to the
small sample size in each stratified category.
PFS
Because the kinetics of posttransplantation im-
mune recovery is expected to significantly affect
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Figure 4. Cumulative incidence of grade II to IV (A) and grade III to IV
(B) acute graft-versus-host disease (aGVHD) and chronic graft-versus-
host disease (cGVHD) (C) after transplantation. Black line shows umbil-
ical cord blood (UCB) recipients, and dotted line shows matched sibling
donor/matched unrelated donor (MSD/MUD) recipients.
Table 3. Comparison of Cumulative Corticosteroid Dose
Corticosteroid Exposure No.
UCB
Median AUC (Range)
For all patients
0-3 months 29 41.8 (0-247)
0-6 months 26 59 (0-285)
0-12 months 21 96 (0-301)
For patients who received
corticosteroids
0-3 months 18 60 (24-247)
0-6 months 23 78 (24-285)
0-12 months 23 109 (24-301)
UCB indicates umbilical cord blood; MSD, matched sibling donor; MUD, matc
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graft type for all consecutive patients (n 5 146) who
underwent HCT at our center, and met the predefined
eligibility criteria for this study. PFS at 1 year forUCB,
MSD, and MUD recipients was 0.59 (95% CI, 0.44-
0.72), 0.49 (95% CI, 0.34-0.62), and 0.56 (95% CI,
0.40-0.69), respectively, without significant difference
between the 3 groups (log-rank test; P 5 .581;
Figure 6A). Cumulative incidence of TRM at 1 year
for UCB, MSD, and MUD recipients was 0.28 (95%
CI, 0.16-0.41), 0.10 (95% CI, 0.04-0.20), and 0.16
(95% CI, 0.07-0.28), respectively (Gray test,
P 5 .030). Causes of treatment-related death within
1 year after transplantation are shown in Table 5.
We then compared PFS among the patients in whom
immune reconstitution was assessed. This select group
of patients survived at least 3 months after transplanta-
tion in order to be evaluable for immune recovery.
There continued to be no statistical difference in
PFS in UCB, MSD, and MUD recipients when the
analysis included both standard-risk and high-risk pa-
tients (PFS at 1 year; 0.85; 95% CI, 0.64-0.94; 0.65;
95% CI, 0.46-0.79; and 0.68; 95% CI, 0.49-0.82;
respectively; log-rank test, P 5 .095; n 5 95;
Figure 6B) or when the analysis was limited to patients
with standard-risk hematological malignancies (PFS at
1 year; 0.81; 95% CI, 0.57-0.92; 0.67; 95% CI,
0.44-0.82; and 0.76; 95% CI, 0.55-0.89, respectively;
log-rank test, P 5 .357; n 5 76; Figure 6C).
To assess the impact of recovery of specific lym-
phocyte subsets on PFS, we tested the various immune
cell populations at 3 months after transplantation and
other clinical factors on their ability to predict PFS us-
ing a 3-month landmark analysis among evaluable 69
patients (regardless of donor type) with standard-risk
hematological malignancies. Patient characteristics
were not associated with PFS in the univariate analysis.
In the bivariate analysis controlling for donor type,
higher numbers of T cells (P 5 .016), regulatory T
cell (Treg) (P 5 .014), cytotoxic T lymphocyte
(CTL) (P 5 .041), and myeloid DC (P 5 .028) were
significantly associated with improved PFS (Table 6).
In the MSD/MUD group, the myeloid DC subsetNo.
MSD/MUD
P ValueMedian AUC (Range)
66 0 (0-285) .03
49 0 (0-286) <.01
36 74 (0-382) .13
25 64 (10-285) .65
31 78 (10-286) .43
40 106 (19-382) .96
hed unrelated donor; AUC, area under the curve.
Table 4. Recovery of Immune Cell Populations According to the Grade of aGVHD
MSD/MUD Median (Range) at 3 Months UCB Median (Range) at 3 Months P Value
Grade 0-I aGVHD n 5 41 n 5 10
Absolute lymphocyte counts 832 (35-3,359) 1297 (481-5,275) .02
CD3+ T cells 473 (13-2,714) 306 (25-2,986) .30
CD4+ T cells 233 (82-712) 134 (21-743) .13
CD8+ T cells 189 (37-1,734) 33 (2-2,240) .05
B cells (CD19+) 54 (0-496) 663 (0-1,287) <.01
NK cells (CD16+/CD56+) 153 (21-1,203) 373 (223-1,049) <.01
CD4+CD45RA+CD62L+ cells (RTE) 16 (4-333) 1 (0-20) <.01
CD4+CD25+CD62L+ cells (Treg) 49 (18-197) 30 (7-89) <.01
CD8+CD57+CD282 cells (CTL) 24 (1-902) 3 (0-291) .22
CD8+HLA-DR+ cells (activated T cells) 53 (5-919) 11 (0-1,702) .28
CD1232CD11c+ cells (myeloid DC) 4 (0-31) 8 (2-18) <.01
CD123+CD11c2 cells (plasmacytoid DC) 7 (0-39) 12 (5-24) .05
CD3+CD16+CD56+ cells (NKT cells) 35 (3-424) 5 (0-62) <.01
Grade 0-II aGVHD n 5 60 n 5 21
Absolute lymphocyte counts 837 (35-3,359) 911 (310-5,275) .48
CD3+ T cells 529 (13-2,741) 249 (3-2,986) <.01
CD4+ T cells 242 (78-812) 131 (2-743) <.01
CD8+ T cells 219 (37-2,262) 32 (1-2,240) <.01
B cells (CD19+) 35 (0-496) 104 (0-1,287) .01
NK cells (CD16+/CD56+) 160 (21-1,203) 360 (179-1,049) <.01
CD4+CD45RA+CD62L+ cells (RTE) 15 (2-333) 5 (0-25) <.01
CD4+CD25+CD62L+ cells (Treg) 53 (11-197) 28 (0-149) <.01
CD8+CD57+CD282 cells (CTL) 28 (1-902) 3 (0-291) .01
CD8+HLA-DR+ cells (activated T cells) 64 (5-1,923) 13 (0-1,702) .02
CD1232CD11c+ cells (myeloid DC) 3 (0-31) 6 (0-21) <.01
CD123+CD11c2 cells (plasmacytoid DC) 7 (0-39) 10 (3-25) .06
CD3+CD16+CD56+ cells (NKT cells) 37 (3-424) 5 (0-62) <.01
Grade II-IV aGVHD n 5 25 n 5 19
Absolute lymphocyte counts 817 (108-2,879) 478 (130-6,434) .13
CD3+ T cells 608 (82-2,741) 131 (3-2,539) <.01
CD4+ T cells 253 (78-591) 59 (2-1,194) <.01
CD8+ T cells 329 (50-2,262) 32 (1-1,291) <.01
B cells (CD19+) 10 (0-240) 20 (0-781) .77
NK cells (CD16+/CD56+) 160 (15-422) 317 (57-2,686) .01
CD4+CD45RA+CD62L+ cells (RTE) 13 (0-170) 6 (0-25) .09
CD4+CD25+CD62L+ cells (Treg) 54 (11-207) 25 (0-149) .02
CD8+CD57+CD282 cells (CTL) 33 (4-362) 1 (0-103) <.01
CD8+HLA-DR+ cells (activated T cells) 104 (9-1,922) 9 (0-1,226) .01
CD1232CD11c+ cells (myeloid DC) 1 (0-16) 3 (0-46) .65
CD123+CD11c2 cells (plasmacytoid DC) 5 (0-36) 9 (0-80) .77
CD3+CD16+CD56+ cells (NKT cells) 43 (5-157) 5 (0-124) <.01
Grade III-IV aGVHD n 5 6 n 5 8
Absolute lymphocyte counts 550 (108-2,024) 348 (130-6,434) 1.00
CD3+ T cells 305 (82-1,518) 65 (48-2,539) .37
CD4+ T cells 239 (85-591) 51 (9-1,194) .41
CD8+ T cells 179 (50-852) 30 (1-1,291) .85
B cells (CD19+) 9 (0-240) 0 (0-781) 1.00
NK cells (CD16+/CD56+) 121 (15-357) 194 (57-2,686) 1.00
CD4+CD45RA+CD62L+ cells (RTE) 15 (0-59) 6 (0-24) 1.00
CD4+CD25+CD62L+ cells (Treg) 47 (27-207) 21 (0-72) .28
CD8+CD57+CD282 cells (CTL) 7 (4-40) 1 (0-77) .84
CD8+HLA-DR+ cells (activated T cells) 43 (13-417) 2 (0-1,226) 1.00
CD1232CD11c+ cells (myeloid DC) 1 (0-16) 0 (0-46) 1.00
CD123+CD11c2 cells (plasmacytoid DC) 5 (3-36) 6 (0-80) 1.00
CD3+CD16+CD56+ cells (NKT cells) 41 (5-101) 7 (2-124) .99
aGVHD indicates acute graft-versus-host disease; MSD, matched sibling donor; MUD, matched unrelated donor; UCB, umbilical cord blood; NK, natural
killer; RTE, recent thymic emigrant; Treg, regulatory T cell; CTL, cytotoxic T lymphocyte; DC, dendritic cell; NKT, natural killer T cells.
1672 Biol Blood Marrow Transplant 18:1664-1676, 2012J. Kanda et al.was the only significant variable (hazard ratio 4.05;
95% CI, 1.13-14.60; P 5 .032; Table 6).DISCUSSION
The past 10 years have brought great strides toward
improvement in the outcome of UCB transplantationin adult patients [28-31]. Progression-free and overall
survival rates now approach that of HCT from
matched adult donors [32,33]. We, therefore, found it
to be an opportune time to perform a comprehensive
comparison of immune reconstitution in adult
recipients after matched sibling, matched unrelated,
and UCB transplantations. We found that (1)
recovery of critical T cell subsets in the UCB
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Figure 6. Progression-free survival (PFS) after transplantation for all
consecutive patients undergoing hematopoietic cell transplantation
(HCT) during the study period (A) and patients who survived at least
3 months without death or relapse after transplantation (B) all patients,
and (C) standard-risk patients. Black line shows umbilical cord blood
(UCB) recipients, dotted line showsmatched sibling donor (MSD) recip-
ients, and gray line shows matched unrelated donor (MUD) recipients.
Biol Blood Marrow Transplant 18:1664-1676, 2012 1673Immune Recovery after Dual UCB and MSD/MUD HCTrecipientswas delayed but reached levels comparable to
recipients of MSD/MUD transplantation by 12
months after transplantation, (2) NK and B cell
recovery was more rapid in UCB recipients, (3) there
was no significant difference in frequency of recent
thymic emigrant as measured by CD31 T cells
containing TRECs, and (4) the T cell repertoire was
comparably diversified in the UCB and MSD/MUD
recipients at 12 months after transplantation. Finally,
we confirm the finding of others that the PFS
between recipients of UCB and MSD/MUD HCT is
comparable.
The recovery of nearly all the critical T cell subsets
was substantially delayed in the UCB group until 3 to
6 months after transplantation, exposing the patients
to an increased risk of viral infection. In fact, the inci-
dence of CMV reactivation reached a plateau at
2 months after MSD/MUD transplantation, whereas
the incidence continuously increased until 6 months
after UCB transplantation. This translated into a sig-
nificant difference in the incidence of CMV reactiva-
tion between the 2 groups. This prolonged period
of vulnerability in UCB recipients has been described
by others [13,14,34]. However, quantitative
differences in T cell subsets were largely erased by
1 year after transplantation. The kinetics and degree
of immune reconstitution observed in our cohort of
UCB transplantation recipients compares favorably
to an earlier report by Komanduri et al. [8] who found
that the number of CD41 and CD81T cells was very
low at 6 months after transplantation and remains so
even at the 1-year time-point. The likely explanation
for this difference is that our UCB recipients did not
receive ATG as part of the preparative regimen. Our
findings are similar to those reported recently by
Jacobson et al. [14] who compared kinetics of T cell,
B cell, and NK cell recovery in recipients of dual
UCB and MUD transplantation after nonmyeloabla-
tive conditioning. Our study focuses on HCT recipi-ents after myeloablative conditioning and extends the
comparison to include posttransplantation thymic
function as well as TCR diversity.
Quantification of TRECs, which are derived from
RTE, has been used as a surrogate marker for thymic-
dependent T cell maturation. Early recovery of
thymopoietic function after UCB transplantation is
a critical determinant of TRM and morbidity [13].
Previous studies have described highly variable but
generally slow recovery of thymic function as deter-
mined by the presence of peripheral bloodTREC after
UCB transplantation [7-9,13]. In order to assess the
Table 5. Causes of Treatment-Related Death within 1 Year
after Transplantation
UCB MSD MUD
Graft failure 1 (7%) 0 0
GVHD 1 (7%) 0 0
Infection 8 (57%) 1 (20%) 4 (57%)
Organ failure 3 (21%) 2 (40%) 3 (43%)
Other 1 (7%) 2 (40%) 0
Total 14 5 7
UCB indicates umbilical cord blood; MSD, matched sibling donor; MUD,
matched unrelated donor; GVHD, graft-versus-host disease.
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way of cellular immune reconstitution, we compared
TREC recovery in our 2 cohorts. In contrast to other
studies, we assayed TREC frequency from DNA iso-
lated from a purified population of CD31 T cells. Al-
though the number of TRECs tended to be lower in
the UCB group both before and 3 months after trans-
plantation, it was not significantly different at 6 and
12 months after transplantation, mimicking the trend
seen in quantitative T cell subset analysis. One expla-
nation for lower TREC values in the UCB group
may be differences in prior cytotoxic therapy resulting
in thymic damage. Indeed, the UCB group was more
heavily pretreated with only 22% of acute leukemia pa-
tients receiving transplantation in first remission com-
pared to 51% in the MSD/MUD group. It should be
noted that the number of TRECs at 1 year after trans-
plantation remained well below normal regardless of
donor source indicating ongoing impairment of
thymus-dependent T cell recovery, which is consistent
with a previous study analyzing mostly pediatric pa-
tients [35]. Komanduri et al. [8] and Escalon et al.
[36] demonstrate a complete block of thymopoiesis
during the first year after UCB transplantation, which
is in stark contrast to what was observed after HCT
from autologous or adult matched donor transplanta-
tion. However, the observed differencesmay be related
to low total numbers of TREC-containing lymphoid
progenitors passively transferred with the stem cell
graft or use of ATG in the transplantation preparative
regimen. We also analyzed TCR diversity in a subsetTable 6. Improved PFS with Recovery of Specific Lymphocyte Sub
Variables Comparison HR (
T cells (CD3+) High vs low 3.33 (1
Regulatory T cells (CD4+CD25+CD62L+) High vs low 3.84 (1
Cytotoxic T cells (CD8+CD57+CD282) High vs low 3.01 (1
Myeloid dendritic cells (CD1232CD11c+) High vs low 3.66 (1
PFS indicates progression-free survival; MSD, matched sibling donor; MUD, m
Standard-risk patients are divided into the high vs low group according to the m
regulatory T cells, cytotoxic T cells, andmyeloid dendritic cells are 439, 43.9, 19
MSD/MUD group, respectively.
Only significant variables analyzed among the standard-risk patients were shoof 10 patients 1 year after HCT with comparable T
cell recovery, as determined by quantitative T cell sub-
set analysis and TREC output. We were interested to
knowwhether the low but detectable output of RTE in
UCB transplantation recipients was capable of equal-
izing TCR diversity of the adult donor recipients
who benefit from homeostatic expansion of passively
transferred polyclonal memory T cells. Despite this
advantage, we found that the TCR diversity in UCB
recipients was comparable to that of the matched adult
donor recipients.
It is of interest to note that despite the observed de-
lay in quantitative T cell recovery in recipients of
UCB transplantation, we did not observe differences
in PFS compared with the recipients of matched adult
donor transplantation. This can be explained, in part,
by the improvement in supportive care. However, it is
also possible that more prompt recovery of NK cells
andB cells inUCB recipientsmay compensate for early
T cell deficits, although rapid recovery of both of these
cell typesmay partly be due to a compensatory response
to the profound T lymphopenia [37,38]. Tanaka et al.
[39] observed a more rapid expansion of NK cells after
UCB compared to PBSC transplantation. The investi-
gators found that UCB-derived mature (CD161,
CD56dim) and immature (CD162, CD561) popula-
tions of NK cells exert potent cytotoxic activity against
tumor cell lines and exhibit decreased expression of in-
hibitory NKG2A and increased expression of stimula-
tory NKG2C as compared to NK cells that emerge
after matched-related donor transplantation.
Patient age [11,12], incidence and severity of
GVHD [40], intensity of the conditioning regimen
[7,41], and T cell depletion of the donor graft [42]
are all significant parameters that affect the pace and
quality of immune recovery after HCT. Of all these
parameters, patient age and the incidence of aGVHD
differed among the 3 cohorts analyzed in this study.
The younger mean age of UCB recipients is unlikely
to be a significant influence on immune recovery be-
cause all recipients were over age 19, which is reported
to be an age that marks significant decline of thymic
function [12]. The higher observed incidence of acute
grade II to IV and grade III to IV GVHD in thesets among Standard-Risk Patients
Total (n 5 69) MSD/MUD Group (n 5 47)
95% CI) P Value HR (95% CI) P Value
.26-8.84) .016 1.68 (0.61-4.64) .319
.31-11.30) .014 2.72 (0.85-8.71) .093
.05-8.64) .041 2.99 (0.94-9.58) .065
.15-11.67) .028 4.05 (1.13-14.60) .032
atched unrelated donor; HR, hazard ratio; CI, confidence interval.
edian value of each lymphocyte subset. Median value (cells/mL) for T cells,
.0, and 8.8 for all patients, respectively, and 505, 57.8, 23.5, and 7.2 for the
wn.
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deserves further discussion. Grade III to IV aGVHD
contributed to delayed immune reconstitution at
3 months after transplantation in this cohort. There-
fore, it is possible that the delay in immune reconstitu-
tion at 3 months after UCB transplantation was the
result of a high incidence of aGVHD in the UCB
group, although a similar pattern of delayed immune
recovery in the UCB recipients was observed regard-
less of how aGVHD patients were grouped (0-I, 0-II,
II-IV, or III-IV). The high incidence of aGVHD in
our cohort compared with previous UCB reports
may, in part, be due to use of a conditioning regimen
that does not contain ATG.
Any study comparing immune reconstitution after
HCT is subject to a ‘‘survivor bias’’ such that the pa-
tients with the most profound impairment in immune
recovery die from treatment-related complications and
are thus not evaluable for comparison. Although a sur-
vivor bias cannot be completely excluded from this
study, there are 2 factors that suggest it does not exert
amajor influence on the findings of this study. First, we
did not observe any significant difference in PFS in the
3 cohorts of patients assessed in this study (Figure 6).
Second, the incidence of infection-related deaths was
low in both treatment cohorts and, therefore, unlikely
to be a contributing factor to the reported observations
(data not shown). An additional limitation of this study
arises from the fact that due to technical constraints,
we report TREC analysis on a subset of evaluable pa-
tients. We cannot rule out the possibility that elimina-
tion of these subjects resulted in a biased analysis of
this portion of the study.
In conclusion, when compared to recipients of
matched sibling and MUD HCT recipients, UCB
transplantation recipients have slower quantitative re-
covery of T lineage immune cell populations in the
first 6 months, but these differences are erased by
1 year after transplantation. NK and B cell reconstitu-
tion is more rapid in UCB recipients.ACKNOWLEDGMENTS
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Supplementary Figure1. Sequential changes of immune cell populations after transplantation Black line shows matched sibling donor (MSD) recip-
ients, and dotted line shows matched unrelated donor (MUD) recipients. Abbreviations: RTE, recent thymic emigrant; T-reg, regulatory T cell; CTL,
cytotoxic T cell. The median values are shown as dots, and the ends of the whiskers indicate the 25% and 75% percentile values. Median and 5%/
95% percentiles of healthy adults are shown in dotted and solid horizontal lines [44].
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